Personal information

Other IDs

Scopus Author ID: 57194115290

Keywords

CAR T cell therapy, Cellular immunotherapy, B cell lymphoma, Programmed cell death

Countries

United States

Activities

Collapse all

Employment (5)

Dana-Farber Cancer Institute: Boston, US

2022-04-18 to present | Postdoctoral Research Fellow (Medical Oncology)
Employment
Source: Self-asserted source
Michael L Olson

The University of Utah: Salt Lake City, UT, US

2017-09-01 to 2022-04-07 | Graduate Student (Pathology)
Employment
Source: Self-asserted source
Michael L Olson

Medical College of Wisconsin: Milwaukee, WI, US

2015-06-15 to 2017-07-15 | Research Technologist (Microbiology and Molecular Genetics)
Employment
Source: Self-asserted source
Michael L Olson

University of Wisconsin–Whitewater: Whitewater, US

2013-09 to 2015-05 | Undergraduate Research Assistant
Employment
Source: Self-asserted source
Michael L Olson

University of Wisconsin–Whitewater: Whitewater, US

2014-06 to 2014-09 | Undergraduate Research Program Fellow
Employment
Source: Self-asserted source
Michael L Olson

Education and qualifications (2)

The University of Utah: Salt Lake City, UT, US

2017-08-15 to 2022-05-01 | PhD: Microbiology and Immunology (Pathology)
Education
Source: Self-asserted source
Michael L Olson

University of Wisconsin Whitewater: Whitewater, WI, US

2012-09-02 to 2015-05-15 | B.S. Biology: Pre-Biomedical Professions
Education
Source: Self-asserted source
Michael L Olson

Professional activities (5)

Society for Functional Precision Medicine: Boston, US

2021 to present
Membership
Source: Self-asserted source
Michael L Olson

American Society of Hematology: Washington, DC, US

2021 to present
Membership
Source: Self-asserted source
Michael L Olson

Society for Advancement of Chicanos and Native Americans in Science: Santa Cruz, California, US

2018 to present
Service
Source: Self-asserted source
Michael L Olson

American Association of Immunologists: Md., Md., US

2018 to present
Membership
Source: Self-asserted source
Michael L Olson

American Association for Cancer Research: Philadelphia, PA, US

2018 to present
Membership
Source: Self-asserted source
Michael L Olson

Funding (6)

Altering CAR-T cell biology to reduce apoptotic priming and promote survival

2024 to 2026 | Grant
Dana-Farber Cancer Institute (Boston, US)
Source: Self-asserted source
Michael L Olson

Chimeric antigen receptor T cell mediated trogocytosis of CD19 in B cell lymphoma

2020 to 2021 | Grant
American Association of Immunologists (Bethesda, Maryland, US)
Source: Self-asserted source
Michael L Olson

John H. Weis Graduate Student Achievement Award

2020 to 2020 | Award
University of Utah (Salt Lake City, Utah, US)
Source: Self-asserted source
Michael L Olson

Investigation of CD229 CAR T cell therapy for B cell lymphoma

2019 to 2020 | Grant
Huntsman Cancer Institute (Salt Lake City, US)
Source: Self-asserted source
Michael L Olson

Characterization of Unknown Mitochondrial Proteins

2013 to 2015 | Grant
University of Wisconsin–Whitewater (Whitewater, US)
Source: Self-asserted source
Michael L Olson

Investigation of proteins encoded by the mitochondrial genome

2013 to 2014 | Grant
Beta Beta Beta (AL, AL, US)
Source: Self-asserted source
Michael L Olson

Works (20)

Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics

Science Translational Medicine
2024-06-05 | Journal article
DOI: 10.1126/scitranslmed.adk7640
Contributors: Felix Korell; Michael L. Olson; Diego Salas-Benito; Mark B. Leick; Rebecca C. Larson; Amanda Bouffard; Harrison Silva; Alessandro Gasparetto; Trisha R. Berger; Michael C. Kann et al.
Source: check_circle
Crossref

Restricting CAR T Cell Trafficking Expands Targetable Antigen Space

2024-02-11 | Preprint
DOI: 10.1101/2024.02.08.579002
Contributors: Erin A. Morales; Kenneth A. Dietze; Jillian M. Baker; Alexander Wang; Stephanie V. Avila; Fiorella Iglesias; Sabarinath V. Radhakrishnan; Erica Vander Mause; Michael L. Olson; Wenxiang Sun et al.
Source: Self-asserted source
Michael L Olson

Trogocytosis-Resistant CAR T Cells Exhibit Increased Persistence and Prevent Antigen Escape

ASH
2023-11-28 | Conference poster
DOI: 10.1182/blood-2023-187421
Part of ISSN: 0006-4971
Part of ISSN: 1528-0020
Contributors: Kenneth A. Dietze; Michael L. Olson; Etse Gebru; Djordje Atanackovic; Aaron P. Rapoport; Tim Luetkens
Source: Self-asserted source
Michael L Olson

Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity.

Science translational medicine
2023-07-19 | Journal article
DOI: 10.1126/scitranslmed.add7900
PMID: 37467316
Contributors: Erica Vander Mause; Jillian Baker; Kenneth Dietze; Sabarinath Venniyil Radhakrishnan; Iraguha T; Destiny Omili; Davis P; Chidester SL; Modzelewska K; Jens Panse et al.
Source: Self-asserted source
Michael L Olson

Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells.

Cell death & disease
2023-04-13 | Journal article | Author
DOI: 10.1038/s41419-023-05727-x
PMID: 37055388
PMC: PMC10101951
Contributors: Pourzia AL; Michael L Olson; Stefanie Bailey; Boroughs AC; Aryal A; Jeremy Ryan; Marcela Maus; Anthony Letai
Source: Self-asserted source
Michael L Olson
grade
Preferred source (of 2)‎

269 Mitochondrial apoptosis mediates CAR T cell cytotoxicity

Regular and Young Investigator Award Abstracts
2022-11 | Conference poster
DOI: 10.1136/jitc-2022-sitc2022.0269
Contributors: Alexandra Pourzia; Michael Olson; Stefanie Bailey; Aditi Aryal; Jeremy Ryan; Marcela Maus; Anthony Letai MD
Source: Self-asserted source
Michael L Olson

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion.

Leukemia
2022-04-30 | Journal article
DOI: 10.1038/s41375-022-01585-2
PMID: 35490197
Source: Self-asserted source
Michael L Olson

Targeting the tumor microenvironment of Ewing sarcoma

Immunotherapy
2021-12 | Journal article
DOI: 10.2217/imt-2020-0341
Part of ISSN: 1750-743X
Part of ISSN: 1750-7448
Source: Self-asserted source
Michael L Olson

Fast off-rate CD229 chimeric antigen receptor T cells efficiently target multiple myeloma, spare T cells, and exhibit reduced trogocytosis

[]
2021-12-07 | Preprint
DOI: 10.1101/2021.12.06.471279
Source: Self-asserted source
Michael L Olson

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing fratricide and antigen-negative tumor escape while preserving anti-tumor activity

[]
2021-12-07 | Preprint
DOI: 10.1101/2021.12.05.471117
Source: Self-asserted source
Michael L Olson

CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma

ASH
2021-11-05 | Conference poster
DOI: 10.1182/blood-2021-154503
Part of ISSN: 0006-4971
Part of ISSN: 1528-0020
Contributors: Michael Olson; Tim Luetkens; Fiorella Iglesias; Sabarinath Radhakrishnan; Jennie Y. Law; Stephanie Avila; Erica Vander Mause; Nicola J Camp; Erin Morales; Aaron P. Rapoport et al.
Source: Self-asserted source
Michael L Olson

CD19 loss by CAR T cell mediated trogoctyosis is regulated by CAR affinity

AAI Annual Meeting
2021-05-01 | Conference poster
DOI: 10.4049/jimmunol.206.supp.58.03
Part of ISSN: 0022-1767
Part of ISSN: 1550-6606
Contributors: Tim Luetkens; Djordje Atanackovic
Source: Self-asserted source
Michael L Olson

Role of immunotherapy in Ewing sarcoma.

Journal for immunotherapy of cancer
2020-12-01 | Journal article
DOI: 10.1136/jitc-2020-000653
PMID: 33293354
PMC: PMC7725096
Source: Self-asserted source
Michael L Olson

Abstract 3250: CD229-targeted CAR T cell therapy for the treatment of B cell lymphoma

AACR Annual Meeting
2020-08-15 | Conference poster
DOI: 10.1158/1538-7445.am2020-3250
Part of ISSN: 0008-5472
Part of ISSN: 1538-7445
Contributors: Michael L. Olson; Sabarinath V. Radhakrishnan; Tim C. Luetkens; Djordje Atanackovic
Source: Self-asserted source
Michael L Olson

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.

Nature communications
2020-02-07 | Journal article
DOI: 10.1038/s41467-020-14619-z
PMID: 32034142
PMC: PMC7005855
Source: Self-asserted source
Michael L Olson
grade
Preferred source (of 2)‎

The promise of adoptive cellular immunotherapies in hepatocellular carcinoma

OncoImmunology
2019-10-13 | Journal article
DOI: 10.1080/2162402x.2019.1673129
Part of ISSN: 2162-402X
Source: Self-asserted source
Michael L Olson

Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell–Mediated Inflammation and Immunosuppression

Cancer Immunology Research
2019-09 | Journal article
DOI: 10.1158/2326-6066.cir-18-0489
Part of ISSN: 2326-6066
Part of ISSN: 2326-6074
Source: Self-asserted source
Michael L Olson
grade
Preferred source (of 2)‎

The role of surface molecule CD229 in Multiple Myeloma

Journal of Clinical Immunology
2018-10-13 | Journal article
DOI: 10.1016/j.clim.2018.10.006
Source: Self-asserted source
Michael L Olson
grade
Preferred source (of 2)‎

Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis

Scientific Reports
2017-05-03 | Journal article
DOI: 10.1038/s41598-017-01411-1
Source: Self-asserted source
Michael L Olson
grade
Preferred source (of 2)‎

Solution Structure of CCL19 and Identification of Overlapping CCR7 and PSGL-1 Binding Sites

Biochemistry
2015 | Journal article
DOI: 10.1021/acs.biochem.5b00560
Source: Self-asserted source
Michael L Olson
grade
Preferred source (of 2)‎

Peer review (2 reviews for 2 publications/grants)

Review activity for BMC cancer (1)
Review activity for Cell death and differentiation. (1)
How many people are using ORCID?